Over the past decade, the therapeutic strategies for advanced ccRCC have evolved rapidly from a non-specific immune approach to targeted therapy against vascular endothelial growth factor (VEGF), and recently to novel immunotherapy. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.